Purchase Order 75D30124P00053
- Not listed
- The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh awarded a $27,274.50 firm fixed price purchase order to Illumina, Inc. of San Diego, California for lab supplies and MiSeq reagent kits. The contract has no set-aside designation and requires completion by October 14, 2022. The MiSeq reagent kits will support the CDC's genomic sequencing work to advance public health goals such as disease surveillance and outbreak response. Illumina will deliver the...
- The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh awarded a $19,502 purchase order to Illumina, Inc. for ISEQ 100NGS kits. The firm fixed price contract has a period of performance of one day, September 6, 2023. The place of performance will be Illumina's location in Atlanta, Georgia. The CDC is likely procuring the next generation sequencing kits to support genomic surveillance efforts within its broader infectious disease programs. No...
- The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh awarded a firm fixed price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $148,290.40 contract is for the provision of lab supplies, with a completion date of September 8, 2021. Illumina has a history of supporting federal agencies like the NIH, CDC, USDA, and VA with its sequencing instruments, reagents, and services....
- The Centers for Disease Control and Prevention (CDC) Pittsburgh awarded a $23,371 firm fixed-price purchase order to Illumina, Inc. for the ISEQ 100 System on August 24, 2021. The contract, which was completed by September 30, 2023, was issued without a set-aside designation, reflecting Illumina's specialized capabilities in genomic sequencing technology. The ISEQ 100 is a compact, entry-level sequencing instrument designed for targeted genomic analysis applications, supporting the CDC's...
- The Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh awarded Illumina, Inc. a $68,541 purchase order to provide LLUMINA MISEQ SYSTEM REAGENTS. The firm fixed price contract has a period of performance from July 3, 2023 through August 19, 2023. Illumina will deliver its Illumina MiSeq System reagents to support the CDC's genomics and sequencing programs. No subcontractors or set aside designations were identified. The contract award utilizes the...
- The Centers for Disease Control and Prevention (CDC) awarded a $176,623.68 firm fixed price purchase order to Illumina, Inc. for MISEQ REAGENT KITS V3 (600 CYCLE) to be delivered to their Pittsburgh location. The place of performance for this contract is in San Diego, California. The contract period of performance is from September 11, 2023 through November 2, 2023. No subcontractors or set aside designations were identified. The CDC works to protect public health and safety through the...
- This is a firm fixed price purchase order awarded by the Centers for Disease Control and Prevention (CDC) Pittsburgh facility to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $97,020.00 contract is for the provision of lab supplies, with a period of performance through July 29, 2023. There is no set-aside designation indicated. Illumina has previously received prime federal contract awards and subcontracts from agencies like the National...
- This firm fixed-price purchase order was awarded by the Centers for Disease Control and Prevention (CDC) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $85,056.40 contract is for the delivery of laboratory reagents, with an ultimate completion date of July 31, 2022. The contract does not have a set-aside designation. Illumina has previously received federal prime contract and subcontract awards from agencies like the National...
- This federal contract award to Illumina, Inc. is for the purchase of a NEXTSEQ 1000 SEQ SYSTEM, a genetic sequencing instrument, by the Centers for Disease Control and Prevention (CDC) in Pittsburgh, PA. The $159,600.00 firm fixed-price purchase order does not have a set-aside designation. Illumina is a manufacturer and provider of genetic and genomic analysis instruments and reagents, and has received previous prime contract awards from federal agencies like the NIH, USDA, and VA to support...
- Illumina, Inc. was awarded a $11,922.64 purchase order by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh for unspecified goods or services to be delivered to San Diego, California. The award was made on a firm fixed price basis with no set-aside designation. As a manufacturer and provider of sequencing and array-based solutions, Illumina likely will supply various sequencing systems, reagents, consumables, or related bioinformatics products to...
The CDC Pittsburgh awarded a $29,595.03 firm fixed-price purchase order to Illumina, Inc. on August 9, 2024, for NextEra XT Library Preparation kits and related reagent supplies required for the agency's validated MiSeq Next-Generation Sequencing (NGS) assay. This assay supports the identification of HIV genetic mutations associated with drug resistance—a critical capability for HIV surveillance and treatment optimization. The contract, which carries no set-aside designation, will be performed in San Diego, California, with an ultimate completion date of September 30, 2024. As a specialized procurement of proprietary reagents integral to the CDC's existing genomic sequencing infrastructure, the award reflects the essential role Illumina's consumables play in federal public health diagnostic operations. Illumina, Inc., a San Diego-based biotechnology manufacturer specializing in genetic sequencing and genomic analysis technologies, serves as the prime contractor. The company maintains extensive federal contracting relationships across multiple civilian and defense agencies, including a significant $45 million Indefinite Delivery contract with the U.S. Department of Agriculture and substantial awards from the Department of Veterans Affairs, National Institutes of Health, and Department of Defense entities. Illumina's dominant market position in NGS instrumentation and associated consumables positions the company as a critical technology partner for federal infectious disease research, antimicrobial resistance surveillance, and diagnostic initiatives. This CDC purchase order is consistent with Illumina's typical engagement model, wherein task orders and delivery orders for reagent kits and maintenance services are issued under existing relationships to support established genomic research and public health surveillance programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Close Out | $0 | 3/16/26 | |
| P00001 | Funding Only Action | $0 | 10/16/24 | |
| Not listed | Not listed | $29.6k | 8/8/24 |